BD completes Carmel Pharma acquisition

FRANKLIN LAKES, N.J. — Becton, Dickinson and Co. now owns the manufacturer of the PhaSeal system.

BD said it has completed its acquisition of Sweden-based Carmel Pharma. Through the deal, BD now owns Carmel's PhaSeal, a leading closed-system drug transfer device for the safe handling of hazardous drugs that are packaged in vials.

"Carmel Pharma is a leader in an early-stage market with significant long-term growth potential," BD Medical medical surgical systems president Alberto Mas said. "We're excited to begin moving forward to address the critically important issue of hazardous drug exposure to healthcare providers by raising awareness, driving advocacy efforts, developing pharmacy and nursing relationships, and expanding market reach around the world for this product category."